Company: EDSA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001171843-25-003189
Chunk: 111

Company: Edesa Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 2
Chunk 111
---
4. The decrease is related to the grant income associated with the activities under the 2023 SIF Agreement.

			●

			Interest income decreased by $42,000 to $265 for the three months ended March 31, 2025 compared to $43,000 for the same period last year primarily due to lower cash balances.

			●
			
			Foreign exchange loss was $3,000 for the three months ended March 31, 2025 compared to a loss of $2,000 for the three months ended March 31, 2024.

For the three months ended March 31, 2025, our net loss was $1.6 million, or $0.30 per common share, compared to a net loss of $1.9 million, or $0.58 per common share for the three months ended March 31, 2024.

Comparison of the Six Months Ended March 31, 2025 and 2024

Total operating expenses decreased to $3.5 million for the six months ended March 31, 2025 compared to $4.1 million for the six months ended March 31, 2024.

			The following table summarizes our R&D expenses incurred during the six months ended March 31, 2025 and 2024, together with the dollar increase or decrease in those items:

20

			Six Months Ended March 31, 2025 

			Change 

			2025

			2024

			$

			Program-specific external costs:

			EB06

			$
			70,868

			$
			-

			70,868

			EB05

			860,615

			1,157,574

			(296,959
			)

			Other development and discovery programs

			60,553

			147,356

			(86,803
			)

			Total program-specific costs

			992,036

			1,304,930

			(312,894
			)

			Unallocated internal costs

			Non-program specific external costs

			1,190

			7,928

			(6,738
			)

			Unallocated internal costs

			510,898

			567,937

			(57,039
			)

			Total unallocated internal costs